Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nanatinostat - Viracta Therapeutics

Drug Profile

Nanatinostat - Viracta Therapeutics

Alternative Names: CHR-3996; Tractinostat; VRx-3996

Latest Information Update: 06 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chroma Therapeutics
  • Developer Chroma Therapeutics; Viracta Therapeutics
  • Class Amides; Antineoplastics; Pyrimidines; Quinolines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lymphoma
  • Phase I/II Multiple myeloma
  • Preclinical Gastric cancer; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder
  • No development reported Solid tumours

Most Recent Events

  • 04 Dec 2018 Viracta plans a clinical trial for the treatment of EBV-associated Solid tumors in 2019
  • 03 Dec 2018 Viracta Therapeutics and Shenzhen Salubris Pharmaceuticals enters into an exclusive collaboration and licence agreement for Cancer (Viral associated) in China
  • 12 Apr 2018 VRx 3996 is now called Tractinostat
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top